Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Effect of a multi-ingredient based food supplement on sexual function in women with low sexual desire.

Palacios S, Soler E, Ramírez M, Lilue M, Khorsandi D, Losa F.

BMC Womens Health. 2019 Apr 30;19(1):58. doi: 10.1186/s12905-019-0755-9.

2.

Exercise-induced anaphylaxis with an Ayurvedic drug as cofactor: A case report.

Losa F, Deidda M, Firinu D, Martino MLD, Barca MP, Giacco SD.

World J Clin Cases. 2019 Mar 6;7(5):623-627. doi: 10.12998/wjcc.v7.i5.623.

3.

Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.

Vidal J, Bellosillo B, Santos Vivas C, García-Alfonso P, Carrato A, Cano MT, García-Carbonero R, Élez E, Losa F, Massutí B, Valladares-Ayerbes M, Viéitez JM, Manzano JL, Azuara D, Gallego J, Pairet S, Capellá G, Salazar R, Tabernero J, Aranda E, Montagut C.

Ann Oncol. 2019 Mar 1;30(3):439-446. doi: 10.1093/annonc/mdz005.

PMID:
30689692
4.

[2018 Consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary].

Matías-Guiu X, Fusté V, Iglesias L, Balañá C, Concha Á, de la Cruz-Merino L, Nieto B, Pané M, Sanz J, Losa F.

Rev Esp Patol. 2019 Jan - Mar;52(1):33-44. doi: 10.1016/j.patol.2018.08.002. Epub 2018 Oct 10. Review. Spanish.

PMID:
30583830
5.

2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary.

Losa F, Iglesias L, Pané M, Sanz J, Nieto B, Fusté V, de la Cruz-Merino L, Concha Á, Balañá C, Matías-Guiu X.

Clin Transl Oncol. 2018 Nov;20(11):1361-1372. doi: 10.1007/s12094-018-1899-z. Epub 2018 May 28. Review.

6.

A standardized flow cytometry network study for the assessment of circulating endothelial cell physiological ranges.

Lanuti P, Simeone P, Rotta G, Almici C, Avvisati G, Azzaro R, Bologna G, Budillon A, Di Cerbo M, Di Gennaro E, Di Martino ML, Diodato A, Doretto P, Ercolino E, Falda A, Gregorj C, Leone A, Losa F, Malara N, Marini M, Mastroroberto P, Mollace V, Morelli M, Muggianu E, Musolino G, Neva A, Pierdomenico L, Pinna S, Piovani G, Roca MS, Russo D, Scotti L, Tirindelli MC, Trunzo V, Venturella R, Vitagliano C, Zullo F, Marchisio M, Miscia S.

Sci Rep. 2018 Apr 11;8(1):5823. doi: 10.1038/s41598-018-24234-0.

7.

A Nonsteroidal Novel Formulation Targeting Inflammatory and Pruritus-Related Mediators Modulates Experimental Allergic Contact Dermatitis.

Gordon WC, López VG, Bhattacharjee S, Gil DR, Díaz JA, de la Losa FP, Peláez RP, Ferrer CT, Bacchini GS, Jun B, Varoqui H, Bazan NG.

Dermatol Ther (Heidelb). 2018 Mar;8(1):111-126. doi: 10.1007/s13555-018-0223-8. Epub 2018 Feb 16.

8.

SEOM clinical guideline on unknown primary cancer (2017).

Losa F, Soler G, Casado A, Estival A, Fernández I, Giménez S, Longo F, Pazo-Cid R, Salgado J, Seguí MÁ.

Clin Transl Oncol. 2018 Jan;20(1):89-96. doi: 10.1007/s12094-017-1807-y. Epub 2017 Dec 11.

9.

Recommendations of the Spanish Menopause Society on the consumption of omega-3 polyunsaturated fatty acids by postmenopausal women.

Sánchez-Borrego R, von Schacky C, Osorio MJA, Llaneza P, Pinto X, Losa F, Navarro MC, Lubián D, Mendoza N.

Maturitas. 2017 Sep;103:71-77. doi: 10.1016/j.maturitas.2017.06.028. Epub 2017 Jun 24.

PMID:
28778336
10.

First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).

Carrato A, Abad A, Massuti B, Grávalos C, Escudero P, Longo-Muñoz F, Manzano JL, Gómez A, Safont MJ, Gallego J, García-Paredes B, Pericay C, Dueñas R, Rivera F, Losa F, Valladares-Ayerbes M, González E, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).

Eur J Cancer. 2017 Aug;81:191-202. doi: 10.1016/j.ejca.2017.04.024. Epub 2017 Jun 19.

11.

Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer.

Santos C, Azuara D, Garcia-Carbonero R, Alfonso PG, Carrato A, Elez ME, Gomez A, Losa F, Montagut C, Massuti B, Navarro V, Varela M, Lopez-Doriga A, Moreno V, Valladares M, Manzano JL, Vieitez JM, Aranda E, Sanjuan X, Tabernero J, Capella G, Salazar R.

Mol Cancer Ther. 2017 Sep;16(9):1999-2007. doi: 10.1158/1535-7163.MCT-17-0153. Epub 2017 Jun 16.

12.
13.

SEOM Clinical Guideline of localized rectal cancer (2016).

González-Flores E, Losa F, Pericay C, Polo E, Roselló S, Safont MJ, Vera R, Aparicio J, Cano MT, Fernández-Martos C.

Clin Transl Oncol. 2016 Dec;18(12):1163-1171. doi: 10.1007/s12094-016-1591-0. Epub 2016 Nov 30.

14.

Recommendations in the management of epithelial appendiceal neoplasms and peritoneal dissemination from mucinous tumours (pseudomyxoma peritonei).

Barrios P, Losa F, Gonzalez-Moreno S, Rojo A, Gómez-Portilla A, Bretcha-Boix P, Ramos I, Torres-Melero J, Salazar R, Benavides M, Massuti T, Aranda E.

Clin Transl Oncol. 2016 May;18(5):437-48. doi: 10.1007/s12094-015-1413-9. Epub 2015 Oct 21.

PMID:
26489426
15.

Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study.

Garcia-Alfonso P, Chaves M, Muñoz A, Salud A, García-Gonzalez M, Grávalos C, Massuti B, González-Flores E, Queralt B, López-Ladrón A, Losa F, Gómez MJ, Oltra A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD).

BMC Cancer. 2015 Apr 29;15:327. doi: 10.1186/s12885-015-1293-y.

16.

A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features.

Salazar R, Capdevila J, Laquente B, Manzano JL, Pericay C, Villacampa MM, López C, Losa F, Safont MJ, Gómez A, Alonso V, Escudero P, Gallego J, Sastre J, Grávalos C, Biondo S, Palacios A, Aranda E.

BMC Cancer. 2015 Feb 26;15:60. doi: 10.1186/s12885-015-1053-z.

17.

Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer.

García M, Martinez-Villacampa M, Santos C, Navarro V, Teule A, Losa F, Pisa A, Cambray M, Soler G, Lema L, Kreisler E, Figueras A, Juan XS, Viñals F, Biondo S, Salazar R.

BMC Cancer. 2015 Feb 26;15:59. doi: 10.1186/s12885-015-1052-0.

18.

Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer.

Feliu J, Salud A, Safont MJ, García-Girón C, Aparicio J, Losa F, Bosch C, Escudero P, Casado E, Jorge M, Bohn U, Pérez-Carrión R, Carmona A, Custodio AB, Maurel J.

PLoS One. 2015 Jan 20;10(1):e0116527. doi: 10.1371/journal.pone.0116527. eCollection 2015.

19.

Cytoreductive surgery and intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis from colorectal origin.

Losa F, Barrios P, Salazar R, Torres-Melero J, Benavides M, Massuti T, Ramos I, Aranda E.

Clin Transl Oncol. 2014 Feb;16(2):128-40. doi: 10.1007/s12094-013-1053-x. Epub 2013 Jun 6. Review.

PMID:
23740133
20.

Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer.

Carrato A, Gómez A, Escudero P, Chaves M, Rivera F, Marcuello E, González E, Grávalos C, Constenla M, Manzano JL, Losa F, Maurel J, Dueñas R, Massuti B, Gallego J, Aparicio J, Antón A, Aranda E.

Clin Transl Oncol. 2013 Sep;15(9):705-11. doi: 10.1007/s12094-012-0993-x. Epub 2013 Jan 29.

PMID:
23359181
21.

Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages II-III rectal cancer.

Salazar R, Navarro M, Losa F, Alonso V, Gallén M, Rivera F, Benavides M, Escudero P, González E, Massutí B, Gómez A, Majem M, Aranda E.

Clin Transl Oncol. 2012 Aug;14(8):592-8. doi: 10.1007/s12094-012-0846-7. Epub 2012 Jul 11.

PMID:
22855141
22.

First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.

Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Abad A, Valladares M, Rivera F, Safont MJ, Martínez de Prado P, Gallén M, González E, Marcuello E, Benavides M, Fernández-Martos C, Losa F, Escudero P, Arrivi A, Cervantes A, Dueñas R, López-Ladrón A, Lacasta A, Llanos M, Tabernero JM, Antón A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors.

Oncologist. 2012;17(1):15-25. doi: 10.1634/theoncologist.2011-0249. Epub 2012 Jan 10.

23.

[Short stay emergency unit, an aid in the adaptation of admission due to community acquired pneumonia].

Jacob Rodríguez J, Losa FC, Roca LF, Pastor JA.

Rev Clin Esp. 2012 Jan;212(1):51-2. doi: 10.1016/j.rce.2011.06.003. Epub 2011 Jul 27. Spanish. No abstract available.

PMID:
21798533
24.

Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study.

Nogué M, Salud A, Vicente P, Arriví A, Roca JM, Losa F, Ponce J, Safont MJ, Guasch I, Moreno I, Ruiz A, Pericay C; AVACROSS Study Group.

Oncologist. 2011;16(5):614-20. doi: 10.1634/theoncologist.2010-0285. Epub 2011 Apr 5.

25.

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer.

Feliu J, Safont MJ, Salud A, Losa F, García-Girón C, Bosch C, Escudero P, López R, Madroñal C, Bolaños M, Gil M, Llombart A, Castro-Carpeño J, González-Barón M.

Br J Cancer. 2010 May 11;102(10):1468-73. doi: 10.1038/sj.bjc.6605663. Epub 2010 Apr 27.

26.

Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer.

Roca JM, Alonso V, Pericay C, Escudero P, Salud A, Losa F, López LJ, Guasch I, Méndez M, Quintero-Aldana G, Grande C, Vicente P, Arrivi A, Martin C, Moreno I, García P, Antón I, Constenla M, Yubero A, Cirera L; ACROSS Cooperative Group.

Chemotherapy. 2010;56(2):142-6. doi: 10.1159/000313527. Epub 2010 Apr 21.

PMID:
20407241
27.

Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study.

Martin-Broto J, Gutierrez A, Garcia-del-Muro X, Lopez-Guerrero JA, Martinez-Trufero J, de Sande LM, Lainez N, Maurel J, De Juan A, Losa F, Andres R, Casado A, Tejido PG, Blanco R, Carles J, Bellmunt J, Gomez-España A, Ramos R, Martinez-Serra J, Llombart-Bosch A, Poveda A.

Ann Oncol. 2010 Jul;21(7):1552-7. doi: 10.1093/annonc/mdq047. Epub 2010 Mar 15.

PMID:
20231303
28.

Protophormia terraenovae. A new allergenic species in amateur fishermen of Caceres, Spain.

Carreño SP, de la Losa FP, Carrión EF, Martín ER, Cantariño AR, González AS, Trabado AR, Timón SJ, Arenas MA, Velasco VM, Martín MR, Arbeiza JH.

Allergol Immunopathol (Madr). 2009 Mar-Apr;37(2):68-72.

PMID:
19445862
29.

[Colorectal cancer in a population with a guaiac-based screening programme].

Navarro M, Peris M, Binefa G, Vanaclocha M, Losa F, Fernández E.

Med Clin (Barc). 2009 Apr 11;132(13):495-500. doi: 10.1016/j.medcli.2008.12.026. Epub 2009 Apr 7. Spanish.

PMID:
19356774
30.

Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study.

Sastre J, Aranda E, Massutí B, Tabernero J, Chaves M, Abad A, Carrato A, Reina JJ, Queralt B, Gómez-España A, González-Flores E, Rivera F, Losa F, García T, Sanchez-Rovira P, Maestu I, Díaz-Rubio E.

Crit Rev Oncol Hematol. 2009 May;70(2):134-44. doi: 10.1016/j.critrevonc.2008.11.002. Epub 2008 Dec 25.

PMID:
19111473
31.

[Cancer of unknown origin].

Losa F, Camacho L, Valencia JB.

Med Clin (Barc). 2007 Jun 2;129(1):23-6. Review. Spanish. No abstract available.

PMID:
17570183
32.

Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.

Díaz-Rubio E, Tabernero J, Gómez-España A, Massutí B, Sastre J, Chaves M, Abad A, Carrato A, Queralt B, Reina JJ, Maurel J, González-Flores E, Aparicio J, Rivera F, Losa F, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.

J Clin Oncol. 2007 Sep 20;25(27):4224-30. Epub 2007 Jun 4.

PMID:
17548839
33.

XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer.

Feliu J, Salud A, Escudero P, Lopez-Gómez L, Bolaños M, Galán A, Vicent JM, Yubero A, Losa F, De Castro J, de Mon MA, Casado E, González-Barón M.

Br J Cancer. 2006 Apr 10;94(7):969-75.

34.

Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer.

Nogué M, Salud A, Batiste-Alentorn E, Saigí E, Losa F, Cirera L, Méndez M, Campos JM, Galan A, Escudero P, Arcusa A, Manzano H, de Mendizábal EV, de Olaguer JP, Boleda M, Guasch I, Vicente P.

Eur J Cancer. 2005 Oct;41(15):2241-9.

PMID:
16214045
35.

Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS).

Martín J, Poveda A, Llombart-Bosch A, Ramos R, López-Guerrero JA, García del Muro J, Maurel J, Calabuig S, Gutierrez A, González de Sande JL, Martínez J, De Juan A, Laínez N, Losa F, Alija V, Escudero P, Casado A, García P, Blanco R, Buesa JM; Spanish Group for Sarcoma Research.

J Clin Oncol. 2005 Sep 1;23(25):6190-8. Erratum in: J Clin Oncol. 2006 Apr 10;24(11):1784. García, Pilar [corrected to García, Paula].

PMID:
16135486
36.

Phase II study of irinotecan (CPT-11) administered every 2 weeks as treatment for patients with colorectal cancer resistant to previous treatment with 5-fluorouracil-based therapies: comparison of two different dose schedules (250 and 200 mg/m2) according to toxicity prognostic factors.

Saigi E, Salut A, Campos JM, Losa F, Manzano H, Batiste-Alentorn E, Acusa A, Vélez de Mendizabal E, Guasch I, Antón I; ACROSS Cooperative Group.

Anticancer Drugs. 2004 Oct;15(9):835-41.

PMID:
15457123
37.

Zoledronate-induced remission of acute panmyelosis with myelofibrosis.

Español I, Romagosa V, Berlanga J, Domingo A, Losa F, Heras L, Janáriz J.

Eur J Haematol. 2004 Sep;73(3):215-8.

PMID:
15287920
38.

Second-line chemotherapy for non-small cell lung cancer.

Bonfill X, Serra C, Sacristán M, Nogué M, Losa F, Montesinos J.

Cochrane Database Syst Rev. 2002;(2):CD002804. Review.

PMID:
12076452
39.

Second-line chemotherapy for non-small cell lung cancer.

Bonfill X, Serra C, Sacristán M, Nogué M, Losa F, Montesinos J.

Cochrane Database Syst Rev. 2001;(4):CD002804. Review. Update in: Cochrane Database Syst Rev. 2002;(2):CD002804.

PMID:
11687161
40.

Peripheral primitive neuroectodermal tumor (PPNET) of pelvic origin: report of a case arising from an unusual location.

Mata F, Losa F, Camacho L, Fernandez Trigo V, Barrios P, Mas J.

Tumori. 2001 Mar-Apr;87(2):109-11.

PMID:
11401207
41.

[Primary germ cell tumors of the central nervous system].

Losa F, García del Muro J, Germà JR.

Neurologia. 1997 Jun-Jul;12(6):249-54. Review. Spanish.

PMID:
9303592
42.

[Tuberculous pleuritis in pre-existent sarcoidosis].

Hamacher J, Losa F, Im Hof V, Gugger M.

Schweiz Med Wochenschr. 1991 Apr 20;121(16):577-82. German.

PMID:
2042042
43.

[247 episodes of sepsis at a medical department of a district hospital].

Losa F, Pedrazzini GB, Mombelli G.

Schweiz Med Wochenschr. 1989 Oct 7;119(40):1375-81. German.

PMID:
2799346

Supplemental Content

Support Center